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The case presented
Controversies surrounding myalgic encephalo-
myelitis or chronic fatigue syndrome (ME/CFS) 
diagnosis and management (Geraghty, 2016; 
Geraghty and Esmail, 2016) have affected clini-
cal practice and public perceptions and have led 
to disagreements between doctors and patients 
(Campion, 2016). There is still a lack of under-
standing and recognition of ME/CFS among 
many general practitioners (GPs) (Horton et al., 
2010).
One of the main issues has been the absence of 
established diagnostic biomarkers and the reliance 
on diagnostic criteria (with over 20 proposed to 
date) largely based on clinical symptoms for diag-
nosis and research purposes. This has been prob-
lematic, especially when such criteria have been 
broad (Jason et al., 2014; Morris and Maes, 2013) 
and have not stratified cases into sub-groups. The 
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challenge presented by diagnosis misclassifica-
tion, which results in ‘false positives’ (or ‘spuri-
ous’ cases) is evident when prevalence rates of 
ME/CFS using different criteria are compared. A 
systematic review showed a greater than 100-fold 
variation in disease prevalence across studies 
(Brurberg et al., 2014), ranging from 0.1 per cent 
(Nacul et al., 2011) using the Canadian Consensus 
Criteria (Carruthers et al., 2003), a relatively spe-
cific classification which is considered by many to 
most closely represent ‘genuine’ ME/CFS cases, 
to 3.7 and 7.6 per cent in a study using the Oxford 
and Australian definitions, respectively (Lindal 
et al., 2002).
Even if we assume differences in methodol-
ogy and geographical variations in prevalence, 
it is clear that rates are influenced markedly by 
the diagnostic criteria used. Brurberg et al. 
(2014) also showed that the Oxford criteria 
(Sharpe et al., 2015) yielded the highest median 
prevalence across studies, 1.5 per cent, 15 times 
greater than that obtained using the Canadian 
criteria, albeit in different populations. If it is 
assumed that the Oxford criteria always capture 
Canadian-positive cases, then, based on the 
above figures, we expect that of a sample of 15 
cases selected using the Oxford criteria, 14 will 
not meet the Canadian criteria. Therefore, if 
Oxford-positive cases are used to test a hypoth-
esis related to a specific pathophysiological 
process observed in Canadian-positive cases, 
this could lead to the selection of 14 non-cases 
(false positives) for every 15 recruited; an unac-
ceptable level of misclassification.
Implications of diagnosis 
misclassification in 
observational studies
The following hypothetical example illustrates 
the level of bias that could be generated using 
inappropriate case definitions. If the odds ratio 
(OR) for the association of ME/CFS with certain 
exposure variable (V) is 4.0, then the true associa-
tion between V and disease, ascertained using a 
standard diagnostic criteria considered to reflect 
‘actual’ cases, in a case–control study with 300 
incident cases and 300 controls can be repre-
sented in a 2 × 2 table (Table 1). Table 2 illustrates 
the results of a hypothetical study where biased 
case selection resulted in the recruitment of one 
‘actual’ case (associated with V; OR = 4) and 14 
‘spurious’ cases (not associated with V; OR = 1) 
for every 15 cases recruited. The result is a highly 
underestimated OR.
Conversely, if the association exists in ‘spu-
rious’ cases but not in ‘actual’ cases, the result 
could be the finding of false association, with 
an overestimated OR.
Diagnosis misclassification in 
clinical trials
The peril of diagnosis misclassification can be 
illustrated with a hypothetical example on diabe-
tes mellitus. While both the better-known types 
of diabetes (types 1 and 2) share hyperglycaemia 
as the common factor defining the diagnosis, the 
classification of the disease into subtypes is 
essential for effective management and predic-
tion of prognosis. The distinct pathophysiologies 
Table 1. Actual association between exposure to 
variable V and case of disease.
Exposure status Cases Controls
Exposed to V 240 150
Not exposed to V  60 150
OR = (240 × 150)/(150 × 60) = 4.
Table 2. Association between exposure to V and 
case of disease resulting from misclassification of 
cases.
Exposure status Cases Controls
Actual 
cases
Spurious  
cases (false +)
Exposed to V 16 140 150
Not exposed to V  4 140 150
Cases include 14/15 ‘artificial’ (‘spurious’) cases with no 
actual association with V.
OR = (156 × 150)/(150 × 144) = 1.08.
OR (excluding spurious cases) = (16 × 150)/(150 × 4) = 4.
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of the two types of diabetes demand quite differ-
ent approaches: targeting insulin resistance with 
lifestyle changes and/or oral medication for the 
initial management of type 2 diabetes, in contrast 
to mandatory insulin usage for type 1.
Consider a clinical trial of a non-insulin 
hypoglycaemic agent effective against type 2 
diabetes (but not type 1) recruiting cases of both 
type 1 and type 2 diabetes. If recruitment were 
population-based, and because type 2 diabetes 
is much more common than type 1, in the 
absence of stratification, it could be concluded 
that the hypoglycaemic agent is effective in 
reducing blood glucose concentration in all 
cases, as the average decrease in glycaemia 
would be driven by the predominance of study 
participants with type 2 diabetes. This would 
mask the complete ineffectiveness of the treat-
ment among the sub-group of participants with 
type 1 diabetes, for whom the treatment could 
lead to dangerous increases in glucose levels.
Similar problems may well be happening in 
research on other less well-understood diseases 
including ME/CFS, where the danger lies in 
generalising the results of studies using patients 
with unspecific ‘chronic fatigue’ (which could 
include people with a range of diagnoses, includ-
ing mental health conditions) to people with 
ME/CFS. Beth Smith et al. (2014, addendum 
2016) recently reappraised the evidence for 
ME/CFS treatments. When studies using the 
broad Oxford criteria (Sharpe et al., 1991) were 
excluded, a virtual disappearance of effect for 
graded exercise therapy (GET), cognitive 
behaviour therapy (CBT) and other psychologi-
cal therapies recommended by the NICE guide-
lines (National Institute for Health and Care 
Excellence (NICE), 2007) was revealed. Studies 
included the pacing, graded activity, and cogni-
tive behaviour therapy: a randomised evaluation 
(PACE) trial (White et al., 2011) where psycho-
logical and exercise-based treatments had some 
efficacy against chronic fatigue as a symptom in 
the sample., but were shown to have little effect 
for those people with ME/CFS when defined 
according to more restrictive criteria (Beth 
Smith et al., 2014, addendum 2016; Geraghty 
and Esmail, 2016).
The revised understanding of the evidence 
will likely result in changes to ME/CFS treatment 
guidelines, illustrating the potentially far-reach-
ing repercussions of diagnostic misclassification 
and selection bias.
A strategy for research
The understanding of the significant impact 
diagnosis misclassification can have on policy 
and patient care will lead to new research 
opportunities as we embrace well-designed and 
powered studies that recruit patients compliant 
with more specific definitions and include 
detailed phenotyping of participants (Jason 
et al., 2015). One approach to reducing misclas-
sification in observational and interventional 
studies would be to improve specificity in case 
selection by, for example, requiring participants 
to simultaneously meet a combination of 
selected internationally agreed diagnostic crite-
ria to be considered as cases. This would
1. Minimise the recruitment of ‘spurious’ 
cases for studies;
2. Avoid results that are difficult to inter-
pret and represent a waste of precious 
resources;
3. Avoid fallacies in the ‘evidence’, which 
have served neither patients nor health 
professionals.
A natural concern of using very stringent 
diagnostic criteria for research studies is that 
genuine cases could be excluded for not meet-
ing inclusion criteria. While this can happen, 
the main consequence in analytical studies 
would be some reduction in study power, a 
price worth paying for a robust analysis that 
enables unbiased inference. If more laborious 
recruitment is required (as many cases may not 
meet more stringent criteria for inclusion), any 
increase in study costs to achieve a given sam-
ple size would outweigh expenditure on 
research that is flawed by being too inclusive in 
recruitment of cases, but could generate spuri-
ous results. Those results, if interpreted uncriti-
cally, may drain precious resources to no effect.
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Priorities for clinical practice
Nevertheless, it is important to distinguish 
research from clinical practice. While the for-
mer should focus on better definition of disease 
status, sub-groups and the trialling of preventa-
tive and treatment interventions, the main role 
of the clinician is to provide the best care and 
support to their patients, irrespective of a diag-
nosis or lack of it. Therefore, clinical services 
should be open to people with a broader range 
of conditions, presenting with, for example 
chronic fatigue.
Historically, patients accepted by ME/CFS 
Specialist Services in the United Kingdom have 
often been required to meet the centers for dis-
ease control and prevention (CDC)-1994 criteria 
(Fukuda et al., 1994) or even broader case crite-
ria (NICE, 2007). We propose that criteria such 
as the Institute of Medicine (Institute of 
Medicine, 2015) or the CDC-1994 could still be 
used as a guide for primary care professionals to 
refer patients to Specialist Services, provided an 
adequate workout of cases conducted in primary 
care to enable the practitioner to suspect a diag-
nosis of ME/CFS. This could be the case until 
we have a better understanding of ME/CFS and 
are in a position to diagnose reliably and offer 
specific treatments. It is also important to 
acknowledge that many with chronic fatigue 
currently referred to ME/CFS specialist services 
would benefit from alternative care pathways, 
avoiding overloading already stretched services. 
This is particularly important for those with an 
alternative diagnosis explaining their symp-
toms, including some chronic medical and psy-
chiatric diseases. It has been suggested that 
between 40 and 64 per cent of cases referred to 
CFS Specialist services do not meet diagnostic 
criteria for CFS, so robust referral procedures 
need to be established (Devasahayam et al., 
2012; Newton et al., 2010).
Conclusion
The inclusion in research studies of only those 
patients that simultaneously meet a small num-
ber of selected case definitions could improve 
research cost-effectiveness and, by reducing 
bias, optimise the chances of diagnostic bio-
markers discovery and the development of 
effective treatments. A research strategy that 
values robustness of methods will speed the 
process of knowledge generation and its trans-
lation to better clinical practice. The care of 
those with chronic fatigue should continue, 
based on the best existing practice and evi-
dence, when available, in open and transparent 
dialogue with patients. This will enable positive 
relationships built on trust between patients and 
professionals, with informed disease manage-
ment decisions taken in partnership.
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